MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs

Rhea-AI Summary

MiNK Therapeutics (NASDAQ: INKT) will report first quarter 2026 financial results for the period ended March 31, 2026, before market open on May 15, 2026. A conference call and webcast will be held at 8:30 AM ET to review results and provide a corporate update.

The update will cover progress across the iNKT cell therapy platform, including clinical development, translational research, platform expansion, strategic initiatives, continued advancement of lead allo-iNKT therapy agenT-797, recent scientific presentations, and a collaboration with C-Further on a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers. A live webcast and replay will be available on the company website.

Positive

• Advancing lead allo-iNKT therapy agenT-797 across cancer and immune disease settings
• Scientific presentations highlighting platform’s potential role in immune activation and reprogramming
• Collaboration with C-Further to develop PRAME-targeted, TCR-engineered iNKT therapy for pediatric cancers
• Platform designed for off-the-shelf, scalable iNKT cell therapies bridging innate and adaptive immunity

Negative

• None.

News Market Reaction – INKT

-0.82%

-0.82% Session close to close

In the May 11 session, INKT declined 0.82%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for MiNK’s Q1 2026 results on May 15, 2026 and signals a platfo...

Analysis

This announcement sets the timetable for MiNK’s Q1 2026 results on May 15, 2026 and signals a platform-focused update on agenT‑797 and engineered iNKT programs. It follows prior communications about non-dilutive funding and collaborations, including the C‑Further PRAME-targeted TCR‑engineered iNKT effort. Investors may watch for details on cash usage versus the $13.4M year-end 2025 cash and how the existing $150,000,000 shelf and ATM flexibility support ongoing trials.

Key Figures

Share price: $11.04 Market cap: $55,747,450 Shelf registration size: $150,000,000 +5 more

8 metrics

Share price $11.04 Pre-news price on earnings-date announcement

Market cap $55,747,450 Equity value before Q1 2026 results

Shelf registration size $150,000,000 Maximum aggregate offering under S-3 shelf

ATM program size $50,000,000 At-the-market facility through B. Riley Securities

Current ATM capacity $6,641,284 Limit under Instruction I.B.6 based on float

Year-end cash $13.4M Cash balance at end of 2025 (per prior filings)

2025 net loss $12.5M Full-year 2025 net loss reported in 10-K

Earnings call time 8:30 AM ET Scheduled Q1 2026 conference call on May 15, 2026

Previous Earnings date Reports

1 past event · Latest: Mar 17 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 17	Earnings date notice	Positive	+4.9%	Announced FY2025 results date plus iNKT platform expansion and C‑Further collaboration.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The prior earnings-date announcement in March 2026 coincided with a positive 4.93% move, suggesting investors have previously reacted constructively to similar scheduling updates.

Recent Company History

Recent history for MiNK shows steady communication around financial events and platform development. On March 17, 2026, an earnings-date press release with added platform expansion details and a C‑Further collaboration preceded a 4.93% gain. Subsequent releases in late March and April highlighted Q4/FY 2025 results, clinical progress for agenT‑797, and multiple conference presentations. Today’s Q1 2026 earnings-date notice continues this pattern of pairing financial timing with strategic iNKT platform commentary.

Key Terms

allogeneic, invariant natural killer T (iNKT) cell therapies, tcr-engineered, prame-targeted

4 terms

allogeneic medical

"a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural"

Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.

invariant natural killer T (iNKT) cell therapies medical

"pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer"

Invariant natural killer T (iNKT) cell therapies use a specific type of immune cell that combines features of two frontline defenders—T cells and natural killer cells—and are grown or reprogrammed to seek and destroy diseased cells. Think of them as retrained guard dogs taught to recognize particular threats; they matter to investors because successful therapies can offer powerful, potentially durable treatments for cancer and other diseases, but they also carry high clinical, manufacturing and regulatory risk that can strongly affect company value.

tcr-engineered medical

"PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers."

TCR-engineered describes immune cells that have been genetically reprogrammed to carry a specific T-cell receptor, which lets them recognize and attack particular disease markers, most often on cancer cells. For investors, these therapies are important because they represent a precision treatment approach with high upside if effective, but they also carry technical, safety and regulatory risks that can strongly influence a biotech company's valuation and development timeline — think of retraining soldiers to find a hidden enemy, with both potential for decisive wins and costly setbacks.

prame-targeted medical

"Company’s collaboration with C-Further to advance a PRAME-targeted, TCR-engineered"

A prame-targeted therapy or diagnostic focuses on PRAME, a protein that is unusually abundant on certain cancer cells but rare on healthy tissues; the approach aims to find or attack cells displaying that marker. For investors, PRAME-targeted programs matter because they promise more precise treatments or tests—like using a metal detector that beeps only at specific coins—potentially improving effectiveness, reducing side effects, and affecting a drug candidate’s development risk and commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the first quarter ended March 31, 2026, before the market opens on Friday, May 15, 2026.

The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update on recent progress across its iNKT cell therapy platform, including clinical development, translational research, platform expansion, and strategic initiatives.

The update will follow several recent corporate and development milestones, including continued advancement of MiNK’s lead allo-iNKT cell therapy, agenT-797, across cancer and immune-mediated disease settings, recent scientific presentations highlighting the platform’s potential role in immune activation and immune reprogramming, and the Company’s collaboration with C-Further to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers.

MiNK continues to advance a differentiated iNKT platform designed to bridge innate and adaptive immunity, support cytotoxic immune responses, and enable off-the-shelf, scalable cell therapy approaches across high-need disease areas.

Conference Participant Dial Information
United States - New York	(646) 307-1963
USA & Canada - Toll-Free	(800) 715-9871
Conference ID -	4876136

Webcast & Replay Information
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event.

Live event link: https://edge.media-server.com/mmc/p/n4ak2xfn
Webcast Replay: https://investor.minktherapeutics.com/events-and-presentations

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.

Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.

Contacts

Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com

Source: MiNK Therapeutics

FAQ

When will MiNK Therapeutics (INKT) report Q1 2026 financial results?

MiNK will report Q1 2026 results before market open on May 15, 2026. According to the company, a conference call and webcast will follow at 8:30 AM ET to discuss financials and provide a corporate update on platform progress.

How can investors join the MiNK Therapeutics (INKT) Q1 2026 earnings call and webcast?

Investors can join the conference call at 8:30 AM ET on May 15, 2026 or access the live webcast. According to the company, a replay will be available on the Events & Presentations page of the company website after the event.

What program updates will MiNK Therapeutics (INKT) provide on May 15, 2026?

The company will provide updates on clinical development, translational research, platform expansion, and strategic initiatives. According to the company, topics include progress with agenT-797 and scientific presentations supporting the iNKT platform.

What is MiNK’s collaboration with C-Further for INKT about?

MiNK is collaborating with C-Further to advance a PRAME-targeted, TCR-engineered iNKT cell therapy for pediatric cancers. According to the company, the collaboration aims to apply engineered iNKT cells to target PRAME in pediatric oncology.